NCT02711462 - Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Healthy

Interventions

DRUG

PF-06687234

PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses

DRUG

Placebo

In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels